Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use

Highlights:
• Incannex has engaged Catalent for the development and cGMP manufacture of Incannex’s own
psilocybin drug product.
• The psilocybin is designed for use in Incannex’s ongoing psilocybin-assisted psychotherapy
“PsiGAD” clinical development program for generalised anxiety disorder and for potential
future commercial use or supply as a cGMP pharmaceutical grade product.
• Development of the drug product includes generation of the necessary quality and stability data
to support future regulatory filings including IND applications.